New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
04:55 EDTALKS, ALKS, RGDO, RGDO, LXRX, LXRX, ZIOP, ZIOP, RNA, RNA, AUXL, AUXL, XON, XON, SIGA, SIGA, GALE, GALE, MSTX, MSTXBiotech Industry Organization to hold a conference
16h Annual BIO CEO & Investor Conference is being held in New York on February 10-11.
News For ALKS;GALE;SIGA;XON;AUXL;RNA;ZIOP;LXRX;RGDO;MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
08:36 EDTRNAProsensa intends to voluntarily delist from NASDAQ
Subscribe for More Information
08:34 EDTRNAProsensa intends to voluntarily delist from NASDAQ
January 29, 2015
16:35 EDTAUXLEndo sees Auxilium transaction immediately accretive
Endo International plc (ENDP)announced it has completed the acquisition of Auxilium Pharmaceuticals (AUXL) in a transaction valued at $2.6B when announced on October 9, 2014. The closing of the transaction follows the approval of the acquisition by Auxilium's shareholders on January 27 and the receipt of all required regulatory approvals. Rajiv De Silva, president and CEO of Endo, stated, This strategic transaction enhances the organic growth of our branded pharmaceuticals business by adding a broad range of high quality products to our already robust portfolio and expanding our development pipeline. We are excited to deliver on the promise of this combination by leveraging our resources to enhance the performance of XIAFLEX and optimize TESTOPEL and STENDRA. We continue to expect the transaction to be immediately accretive for shareholders and meaningfully accretive each year moving forward. We believe that Endo is now even better positioned to drive growth across our product portfolio and to capitalize on additional future strategic M&A opportunities to create value for shareholders, customers and employees." Auxilium common stock will cease to be traded on the NASDAQ Global Market following the close of trading on January 29.
January 28, 2015
06:19 EDTALKSAlkermes depression drug has significant upside potential, says Citigroup
Subscribe for More Information
January 27, 2015
10:54 EDTZIOPZiopharm February volatility elevated at 135
Subscribe for More Information
09:35 EDTAUXLAuxilium shareholders approve merger with Endo
Subscribe for More Information
January 26, 2015
08:34 EDTXONIntrexon launches tender offer to acquire stake in Exemplar Genetics
Subscribe for More Information
January 25, 2015
12:40 EDTMSTXMast Therapeutics COO Patrick Keran to step down
Mast Therapeutics announced a management change in connection with a restructuring of management to best support the company in its current stage of development. The company's President and COO, Patrick L. Keran, will step down from that role and be leaving the company effective February 28, 2015.
January 22, 2015
14:03 EDTAUXLAuxilium to host special shareholder meeting
Subscribe for More Information
07:27 EDTXONIntrexon 3.75M share Secondary priced at $27.00
The deal size was reduced to $101M in common stock from $150M in common stock. JPMorgan and BofA/Merrill acted as joint book running managers for the offering.
January 20, 2015
16:03 EDTXONIntrexon files to sell $150M in common stock
Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as for strategic acquisitions or investments. J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering. Jefferies is acting as a lead manager for the offering. Griffin Securities and Mizuho Securities are acting as co-managers for the offering.
13:21 EDTZIOP, XONCAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
07:25 EDTGALENoble Financial to hold a conference
Subscribe for More Information
05:54 EDTZIOPStocks with implied volatility movement; ZIOP INVN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use